News

Anacardic acid, a compound found in cashew nuts, promoted myelin regeneration and eased neuronal damage and disability in two mouse models of multiple sclerosis (MS). These protective effects were associated with maturation of myelin-producing cells and production of IL-33, an immune-related molecule with a neuroreparative role in the central…

Mylan announced the launch of a first generic version of Tecfidera, a treatment for relapsing forms of multiple sclerosis (MS). The generic, now approved by the U.S. Food and Drug Administration (FDA), is the first generic of any MS treatment available in an oral solid —…

In people with multiple sclerosis (MS), skin cells show increased amounts of cellular stress in a manner that is distinct from people without MS and from other neurological diseases, new research shows. The findings were published in the journal Aging, in the study “Signatures of cell…

In a $3.68 billion transaction, Sanofi is preparing to acquire Principia Biopharma, a biopharmaceutical company focused on the development of therapies for disorders caused by dysregulation of the immune system, including multiple sclerosis (MS). The decision was unanimously approved by the board of directors of…

A protein known as Gsta4 is critical in the growth and activity of oligodendrocytes, a special type of brain cell that generates the myelin sheath that is damaged in multiple sclerosis (MS), a study shows. The overproduction of Gsta4 in…

The degree to which people with multiple sclerosis (MS) are conscientious — a personality trait that reflects responsibility, organization, and goal-oriented skills — in their work habits can help to predict their employment status in three years, according to a survey of 70 MS patients. A study based on…

Urinary tract infections are a common cause of hospitalization among people with multiple sclerosis (MS), especially older patients with progressive disease, and more attention should be given to their bladder, catheter, and general physical care, a U.K. study reported. These infections are often linked to an emergency hospital admission, and…

Lowering levels of a protein called reelin — which regulates how permeable blood vessels are to immune cells — reduced infiltration of these cells into the central nervous system (CNS), preventing neuroinflammation and disease progression in a mouse model of multiple sclerosis (MS). These data, which also showed that Reelin…

Almost two-thirds of people newly diagnosed with multiple sclerosis (MS) in the United States, identified through a national database, were not prescribed disease-modifying therapies (DMTs) over an average of more than two years of follow-up, a real-world study of nearly 5,700 patients found. Current guidelines “recommend early treatment with…

Multiple sclerosis (MS) patients have high levels of cortisol, a stress hormone, compared to healthy controls. Also, patients categorized as non-cognitive fatigue show a higher variability in cortisol levels and perform worse on an attention task. Those findings are documented in the study, “Relation between cognitive fatigue and circadian…

The corticosteroid methylprednisolone is detected at low, safe levels in the breast milk of women with multiple sclerosis (MS) during and after intravenous (into-the-vein) treatment for a postpartum relapse, according to a small study in Turkey. While these findings suggest that women can safely breastfeed their child during and shortly after…

Inflammation drives the loss of brain volume and thinning of the eye’s retina in the first five years of a multiple sclerosis (MS) diagnosis, an imaging study demonstrates.  The findings support a therapeutic strategy of halting inflammatory activity during this initial period. …

Aubagio (teriflunomide), taken as a 14 mg tablet once a day, shows long-term safety and efficacy in patients with relapsing forms of multiple sclerosis (MS), according to results of the Phase 3 TOWER extension study. Treatment was generally well tolerated by the 751 patients using Aubagio for a median…

Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl fumarate), according to real-world data based on two years of therapy. Rituximab’s effectiveness appeared to be comparable to that of Tysabri (natalizumab), but with fewer…

Helius Medical Technologies has filed an application with the U.S. Food and Drug Administration (FDA) asking for de novo classification and clearance of its portable neuromodulation stimulator (PoNS) device for the treatment of walking deficits in multiple…

For the first time, scientists have shown that a protein known as CD36 on the surface of some immune cells is crucial for clearing myelin debris and suppressing nerve cell inflammation in disorders such as multiple sclerosis (MS), according to a new…

About 20%, or 1 in 5, multiple sclerosis (MS) patients fail to adhere to oral disease-modifying therapies (DMTs) taken each day, and about 1 in 4 stop using a prescribed daily oral treatment within one year, a study based on reported real-world use found. The study “Real-world adherence to,…

Therapeutics Solutions International has announced filing a new patent covering the memory protective effects of its natural nutritional supplement QuadraMune, as seen in an animal model of memory loss caused by inflammation. QuadraMune is a nutritional supplement, available in capsule form, made of four ingredients with known anti-inflammatory, neuroprotective, and…

Novartis‘ ofatumumab outperformed Aubagio (teriflunomide) at lowering the frequency of relapses and preventing disability progression among people with relapsing forms of multiple sclerosis (MS), a study based on clinical trial data reports. The study, “Ofatumumab versus Teriflunomide in Multiple Sclerosis,” was published in…

Multiple sclerosis (MS) patients have a greater risk of infections, particularly urinary and kidney infections, around the time of their diagnosis, compared with individuals without MS, a large Swedish population-based study found. Rates of serious and non-serious infections, as well as infections caused by bacteria, virus, and fungus, also…

Donepezil — an approved treatment for Alzheimer’s disease — eased cognitive impairment, depression, and improved other quality-of-life measures in multiple sclerosis (MS) patients with mild to moderate disability, according to results of a single-site clinical trial. The study, “Effect of Donepezil on Cognitive Impairment, Quality of Life, and Depression…

Cigarette smoking and an Epstein–Barr virus infection together represent a significant risk factor for multiple sclerosis (MS), suggesting that at least one path to this disease involves two factors working synergistically, a study reports. The study, “Smoking and Epstein–Barr virus infection in multiple sclerosis development,” was published…

Drinking coffee each day appears to help people with multiple sclerosis (MS) and milder disability and fatigue, with this patient group reporting in a questionnaire that caffeine allowed them to better concentrate on tasks and broaden their attention spans, a study reports. Its researchers suggest that “for selected patients” regular coffee…

A $41,000 fellowship from the National Institutes of Health (NIH) aims to advance research into how changes in brain connectivity are related to the cognitive deficits seen in people with multiple sclerosis (MS). The Ruth L. Kirschstein National Research Service Award Individual Predoctoral Fellowship was granted to…

Immunic Therapeutics‘s IMU-838, a selective immune system modulator, can safely lower the number of brain lesions in people with relapsing-remitting multiple sclerosis (RRMS), top-line Phase 2 clinical trial data suggest. Findings show the trial met its primary goal with statistical significance — a reduction in active lesions (gadolinium…

Immigrants with multiple sclerosis (MS) in Ontario use public health services as much as long-term residents, but are more likely to be hospitalized during the year in which they are diagnosed, according to a recent study. While reasons for that year’s higher hospitalization rates are not clear, evidence supports…

People with multiple sclerosis (MS) who exercise regularly are able to maintain volume in the hippocampus, a brain region responsible for learning and memory, a study reports. This work “adds to the growing body of evidence that exercise has many benefits for people with MS,” the National MS…

Walking abilities decline earlier and faster than arm and hand function in people recently diagnosed with multiple sclerosis (MS), particularly those with progressive MS (MS), a study showed. These findings, which are consistent with those reported in a previous natural history study called NARCOMS, suggest an ascending order of…

The debilitating mental fatigue that people with multiple sclerosis (MS) can feel after a cognitively demanding task may be due to less efficient use of the brain, a pilot study that mapped brain activity during tasks suggests. The study “Neural mechanisms underlying state mental fatigue in multiple sclerosis: a…

Clinical evaluation of multiple sclerosis (MS) patients should include the assessment of lower urinary tract symptoms (LUTS) alongside neurological ones, according to a recent study. The study, “Lower urinary tract dysfunction in patients with multiple sclerosis: A post-void residual analysis of 501 cases,” was published in…